Track topics on Twitter Track topics that are important to you
Today, Pfizer launched its 2016 Annual Review, which provides an in-depth look at all of the ways Pfizer is accelerating patient impact and fulfilling its purpose: to make innovative medicines and vaccines that significantly improve people’s lives.
Every day we use our knowledge, expertise and resources to find new ways to positively impact public health, which in turn advances other global development objectives. We call this approach to global health “Entrepreneurship for Good,” and we are committed to using this approach to help achieve the United Nations Sustainable Development Goals (SDGs).
In the Annual Review, we share more about our commitment to the UN SDGs. Some of the 2016 achievements include:
Along with these achievements, Pfizer also increased its position on the Access to Medicine Index among the top 20 pharmaceutical companies from position 16 in 2014 to position 14 in 2016. Several factors contributed to our higher score, including structured donation programs, nearly doubling the size of our pipeline through research and development efforts, widespread enhancements of pricing, manufacturing and distribution efforts and strengthening our approach to building supply chains.
Learn more about the ways we’re helping all individuals everywhere live healthier lives: www.pfizer.com/annual.
* Data on file. Pfizer Inc., New York, NY.
KEYWORDS: Reports, Environment & Climate Change, Pfizer, ReportAlert, Sustainable Development Goals (SDGs)
Original Article: Pfizer Launches 2016 Annual Review Highlighting Commitment to UN SDGsNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...